Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Breaux Castleman sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director now directly owns 25,183 shares in the company, valued at approximately $1,510,980. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ IONS traded down $0.69 during midday trading on Monday, hitting $59.40. 501,079 shares of the company traded hands, compared to its average volume of 939,122. The company has a debt-to-equity ratio of 0.51, a current ratio of 9.91 and a quick ratio of 9.83. The company has a market cap of $8.37 billion, a PE ratio of 54.00 and a beta of 1.68. The company's 50-day simple moving average is $56.62 and its 200-day simple moving average is $56.42. Ionis Pharmaceuticals Inc has a 52 week low of $39.32 and a 52 week high of $73.09.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $133.00 million for the quarter, compared to the consensus estimate of $161.59 million. Ionis Pharmaceuticals had a net margin of 16.79% and a return on equity of 12.50%. The firm's revenue was down 55.2% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. On average, research analysts predict that Ionis Pharmaceuticals Inc will post -0.48 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of IONS. NEXT Financial Group Inc grew its position in shares of Ionis Pharmaceuticals by 13.7% during the 1st quarter. NEXT Financial Group Inc now owns 1,604 shares of the company's stock valued at $76,000 after acquiring an additional 193 shares during the period. Comerica Bank grew its position in shares of Ionis Pharmaceuticals by 1.3% during the 4th quarter. Comerica Bank now owns 15,879 shares of the company's stock valued at $946,000 after acquiring an additional 205 shares during the period. KBC Group NV grew its position in shares of Ionis Pharmaceuticals by 3.0% during the 4th quarter. KBC Group NV now owns 9,875 shares of the company's stock valued at $597,000 after acquiring an additional 289 shares during the period. HighTower Advisors LLC boosted its holdings in Ionis Pharmaceuticals by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 12,178 shares of the company's stock worth $570,000 after buying an additional 289 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in Ionis Pharmaceuticals by 14.8% in the 1st quarter. US Bancorp DE now owns 2,279 shares of the company's stock worth $107,000 after buying an additional 294 shares during the last quarter. Hedge funds and other institutional investors own 84.02% of the company's stock.
A number of research firms have recently commented on IONS. Royal Bank of Canada began coverage on Ionis Pharmaceuticals in a research note on Tuesday, May 12th. They set an "outperform" rating and a $71.00 target price on the stock. Morgan Stanley increased their price objective on Ionis Pharmaceuticals from $48.00 to $51.00 and gave the stock an "underweight" rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on Ionis Pharmaceuticals from $58.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday, March 9th. ValuEngine cut Ionis Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, April 30th. Finally, BidaskClub raised Ionis Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of "Hold" and a consensus target price of $73.13.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More: Are sell-side analysts objective?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Boring Stocks That Are Winners
Some stocks just don’t get much attention during bull markets. They can be too boring for a growth portfolio. But when the market is going through a period of volatility and uncertainty, these tried-and-true performers have a way of making their way back to popularity.
And there are good reasons for this. First, many of these boring stocks pay dividends. This simply means that the company will reward shareholders simply for holding on to its stock. Dividend stocks aren’t designed to make you rich quickly. However they are designed to offer investors an amount of predictability. And we could all use a little bit of that right now.
And predictable stocks can also help investors manage risk. It can be fun to invest in speculative stocks. But they include a risk premium. When these stocks go up (as they sometimes do) they usually have a return that exceeds the broader market. But when they go down (and they usually do) they usually go down more than the broader market.
But “boring” stocks tend to move closer to the broader market. If you want an analogy from current events, these stocks flatten the curve. They won’t soar as high as riskier stocks, but they won’t sink as low either. And right now, preserving capital should be the number one item on every investor’s checklist.
With that in mind, we’ve created this special presentation to highlight 7 conservative stocks that can help investors win this moment in time. Many of them pay dividends; some do not. But they all have solid fundamental reasons to own them now.
View the "7 Boring Stocks That Are Winners".